Insider Sales: Versant Disposes 224,974 LENZ Shares at $45–$47
Rhea-AI Filing Summary
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
Positive
- Full disclosure of sale quantities, weighted‑average price ranges, and post‑transaction beneficial ownership
- Related‑party structure (GP/LP chain) and signatures included, clarifying voting and dispositive power
Negative
- Insiders sold a total of 224,974 shares on 09/30/2025, which is a material sale by major holders
- Weighted‑average prices are reported without per‑trade breakdowns in the form (available upon request only)
Insights
Insiders sold 224,974 LENZ shares on 09/30/2025, while retaining substantial holdings.
The Form 4 shows coordinated sales by multiple affiliated Versant entities executed across price ranges of $45.00–$47.02, reported as weighted averages. Although a material block of shares was sold (224,974 total), the filing also discloses large remaining positions—several entities report six‑ and seven‑figure share counts, indicating continued significant ownership.
This matters because insider sales combined with sustained large holdings reflect a rebalancing by a major investor rather than a full exit; the chain of GP entities and footnotes clarify indirect ownership and shared voting/investment power.
Reporting complies with Section 16 disclosure: weighted‑average prices and GP/LP relationships are documented.
The Form 4 includes explanatory footnotes stating that prices are weighted averages from multiple transactions and outlines the GP/LP structure (e.g., VV VI GP, VV VII GP, VV II GP-GP) that may share dispositive power. Signatures from Max Eisenberg are present for each reporting entity with dates of 10/02/2025.
These explicit disclosures satisfy common SEC Form 4 transparency requirements by identifying transaction dates, amounts, post‑transaction beneficial ownership, and the nature of indirect holdings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 49,701 | $45.3547 | $2.25M |
| Sale | Common Stock | 34,405 | $45.3547 | $1.56M |
| Sale | Common Stock | 83,066 | $46.4068 | $3.85M |
| Sale | Common Stock | 57,502 | $46.4068 | $2.67M |
| Sale | Common Stock | 177 | $47.0133 | $8K |
| Sale | Common Stock | 123 | $47.0133 | $6K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
